Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Nuvation Bio Inc. Director's Dealing 2025

Nov 24, 2025

32154_dirs_2025-11-24_3a313187-0ac4-448e-bcb4-995c425eed68.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nuvation Bio Inc. (NUVB)
CIK: 0001811063
Period of Report: 2025-11-20

Reporting Person: Hattersley Gary (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-11-20 Class A Common Stock M 69051 $1.74 Acquired 69051 Direct
2025-11-20 Class A Common Stock S 69051 $7.227 Disposed 0 Direct
2025-11-20 Class A Common Stock M 300000 $1.94 Acquired 300000 Direct
2025-11-20 Class A Common Stock S 300000 $7.227 Disposed 0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-11-20 Stock Option (Right to Buy) $1.74 M 69051 Disposed 2030-01-21 Class A Common Stock (69051) Direct
2025-11-20 Stock Option (Right to Buy) $1.94 M 300000 Disposed 2033-02-27 Class A Common Stock (300000) Direct

Footnotes

F1: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $7.15 to $7.43. The Reporting Person will provide, upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F2: Options vested as to 25% on July 1, 2020 and in equal monthly installments thereafter over the following three years.

F3: Options vested as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.